Pfizer Inc. may have skewed the results of studies testing possible off-label uses for the epilepsy drug Neurontin, a new analysis of research data has concluded. In the study, published in the New England Journal of Medicine, researches found inconsistencies including reporting positive results in trials that were initially found to be negative, and the altering of study goals. In a statement, the company denied that it attempted to mislead doctors about off-label uses for Neurontin.